
样式: 排序: IF: - GO 导出 标记为已读
-
Comprehensive Multidisciplinary Evaluation of Dysphagia Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-21 Jessica W. Gregor, David G. Lott, Allon Kahn
-
Gender-Equity Model for Liver Allocation Using Artificial Intelligence (GEMA-AI) for Waiting List Liver Transplant Prioritization Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-21 Antonio Manuel Gómez-Orellana, Manuel Luis Rodríguez-Perálvarez, David Guijo-Rubio, Pedro Antonio Gutiérrez, Avik Majumdar, Geoffrey W. McCaughan, Rhiannon Taylor, Emmanuel A. Tsochatzis, César Hervás-Martínez
We aimed to develop and validate an artificial intelligence score (gender-equity model for liver allocation using artificial intelligence [GEMA-AI]) to predict liver transplant (LT) waiting list outcomes using the same input variables contained in existing models.
-
Lifestyle and Pharmacologic Approaches to Prevention of Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-10 Makan Cheraghpour, Behzad Hatami, Amit G. Singal
Hepatocellular carcinoma (HCC) is a major concern for public health. Fatty liver disease, related to alcohol misuse or metabolic syndrome, has become the leading cause of chronic liver disease and HCC. The strong association between type 2 diabetes mellitus and HCC can be partly attributed to the development of metabolic dysfunction-associated steatotic liver disease (MASLD). There is a strong interest
-
Gastrointestinal and Liver Adverse Effects of Alcohol Use Disorder Medications: A Pharmacovigilance Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-10 Soo Young Hwang, Jay Luther, Wei Zhang
-
Noncolorectal Cancer Screening and Vaccinations in Patients With Inflammatory Bowel Disease: Expert Review Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-10 Freddy Caldera DO PhD, Sunanda Kane MD MSPH, Millie Long MD MPH, Jana G. Hashash MD MSc
The aim of this American Gastroenterological Association (AGA) Clinical Practice Update (CPU) is to provide Best Practice Advice statements for gastroenterologists and other healthcare providers who provide care to patients with inflammatory bowel disease (IBD). The focus is on IBD-specific screenings (excluding colorectal cancer screening, which is discussed separately) and vaccinations. We provide
-
Point-of-Care Ultrasound in Gastroenterology and Hepatology Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-08 Nagasri Shankar, Lily Kuo, Noa Krugliak Cleveland, Benjamin Galen, Nicholas S. Samel, Ariadna Perez-Sanchez, Robert Nathanson, Elizabeth Coss, Juan Echavarria, David T. Rubin, Nilam J. Soni
Point-of-care ultrasound (POCUS) is changing the practice of nearly all specialties and is increasingly being incorporated as a bedside tool by more gastroenterologists and hepatologists. POCUS is most often used to answer focused clinical questions, supplement the traditional physical examination, and guide performance of invasive bedside procedures. This review describes several common POCUS applications
-
-
Twin Pregnancies in Inflammatory Bowel Disease Are Associated With Increased Adverse Outcomes Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-03 Elena F. Cattaneo, Eugenia Shmidt, Ariella Bar-Gil Shitrit, Pranavi Nara, Raina Shivashankar, Sunanda Kane
-
Bouveret Syndrome Treated With Endoscopic Lithotripsy and Gallbladder Access via Cholecysto-duodenal Fistula Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-30 Dexin Chen, Yaqi Zhai, Mingyang Li
-
Differential Efficacy of Advanced Therapies in Inducing Remission in Ulcerative Colitis Based on Prior Exposure to TNF Antagonists Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-26 Han Hee Lee, Virginia Solitano, Sujay Singh, Ashwin N. Ananthakrishnan, Vipul Jairath, Gaurav Syal, Brigid S. Boland, Pradipta Ghosh, John T. Chang, Siddharth Singh
We sought to ascertain how prior exposure to tumor necrosis factor (TNF) antagonists impacts treatment response with various classes of advanced therapies in patients with ulcerative colitis (UC), through a systematic review and meta-analysis.
-
Modified Crohn’s Disease Exclusion Diet Maintains Remission in Pediatric Crohn’s Disease: Randomized Controlled Trial Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-26 Rotem Sigall Boneh, Víctor Manuel Navas-López, Séamus Hussey, Gemma Pujol-Muncunill, Sally Lawrence, Helena Rolandsdotter, Anthony Otley, Javier Martín-de-Carpi, Lee Abramas, Marta Herrador-López, Natalia Egea Castillo, Min Chen, Michelle Hurley, Kirsten Wingate, Ola Olen, Tintin Eurenius Rääf, Michal Yaakov, Nicolette Wierdsma, Johan Van Limbergen, Eytan Wine
The Crohn’s disease exclusion diet (CDED) + partial enteral nutrition (PEN) is effective for inducing remission in mild-moderate Crohn’s disease (CD). We assessed whether a 2-week course of exclusive enteral nutrition (EEN) followed by CDED+PEN is superior to 8 weeks of EEN in sustaining clinical remission at week 14 in mild-to-severe CD and if CDED+PEN can maintain remission to week 24.
-
Incidence of Hepatobiliary Malignancies in Primary Sclerosing Cholangitis: Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-19 Matheus Souza, Luan C.V. Lima, Lubna Al-Sharif, Daniel Q. Huang
Primary sclerosing cholangitis (PSC) is a known risk factor for hepatobiliary malignancies. We conducted a systematic review and meta-analysis of published studies to determine the incidence and risk factors for hepatobiliary malignancies in people with PSC.
-
Resolution of Metabolic Dysfunction-associated Steatohepatitis With No Worsening of Fibrosis After Bariatric Surgery Improves 15-year Survival: A Prospective Cohort Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-19 Guillaume Lassailly, Robert Caiazzo, Armelle Goemans, Mikael Chetboun, Viviane Gnemmi, Julien Labreuche, Gregory Baud, Helene Verkindt, Camille Marciniak, Naima Oukhouya-Daoud, Line-Carolle Ntandja-Wandji, Massih Ningarhari, Emmanuelle Leteurtre, Violeta Raverdy, Sébastien Dharancy, Alexandre Louvet, François Pattou, Philippe Mathurin
The aim of this study was to investigate the consequences of the histological progression of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis on long-term survival after bariatric surgery.
-
Predictors of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Comprehensive Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Azizullah Beran, Tarek Aboursheid, Adel Hajj Ali, Tarek Nayfeh, Hashem Albunni, Alejandra Vargas, Mouhand F. Mohamed, Khaled Elfert, Mohammad Shaear, Ite Obaitan, Nasir Saleem, Awais Ahmed, Mark A. Gromski, John M. DeWitt, Mohammad Al-Haddad, James L. Watkins, Evan Fogel, Jeffrey J. Easler
Pancreatitis is the most common serious adverse event associated with endoscopic retrograde cholangiopancreatography (ERCP). This meta-analysis aimed to precisely assess the risk factors for post-ERCP pancreatitis (PEP).
-
Functional Lumen Imaging Probe Provides an Accurate Assessment of Esophageal Diameter in Patients With Eosinophilic Esophagitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Ronak V. Patel, Dustin A. Carlson, Angelika Zalewski, Nirmala Gonsalves, John Pandolfino, Ikuo Hirano
-
High Risk of Digestive Cancers in Patients With Celiac Disease: A Nationwide Case-Control Cohort Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Anne-Sophie Jannot, Yannick Girardeau, Stanislas Chaussade, Romain Coriat, Nadine Cerf-Bensussan, Georgia Malamut
-
Temporal Changes in Risk Factors of Hepatocellular Carcinoma in a Prospective Cirrhosis Cohort Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 George Cholankeril, Aaron P. Thrift, Saira Khaderi, Fasiha Kanwal, Hashem B. El-Serag, THCCC Working Group, Hao Duong, Amit G. Singal, Sumeet K. Asrani, Themistoklis Kourkompetis, Asif Zamir, Jorge A. Marrero, Ruben Hernaez, Michelle Luster, Abeer Al-Sarraj, Emad Salem
-
Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021 Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Pojsakorn Danpanichkul, Kanokphong Suparan, Chuthatip Kaeosri, Pimtawan Jatupornpakdee, Abdelrahman M. Attia, Thanathip Suenghataiphorn, Jerapas Thongpiya, Banthoon Sukphutanan, Daniel Q. Huang, Mazen Noureddin, Amit G. Singal, Karn Wijarnpreecha, Ju Dong Yang
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are the leading causes of liver disease and are emerging as the main risk factors for primary liver cancer (PLC). However, updated global data on MASH remain scarce.
-
Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn’s Disease; A Prospective Multicenter Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Kento Takenaka, Tadakazu Hisamatsu, Taku Kobayashi, Hironori Yamamoto, Naoki Ohmiya, Ryohei Hayashi, Katsuyoshi Matsuoka, Masayuki Saruta, Akira Andoh, Norimasa Fukata, Kenji Watanabe, Hiroyuki Imaeda, Fumihito Hirai, Takayuki Matsumoto, Akihiro Hirakawa, Tomonori Yano, Minoru Matsuura, Ryuichi Okamoto, Kazuo Ohtsuka, Mamoru Watanabe
Although biologic therapy has revolutionized the treatment of Crohn’s disease (CD), surgery remains unavoidable in cases involving ileal complications. We aimed to evaluate the efficacy of biologics on proximal ileal lesions using balloon-assisted enteroscopy (BAE).
-
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Silvio Danese, Michael E. Rothenberg, Jeremy J. Lim, Han Ting Ding, Jacqueline M. McBride, Yiling Chen, Ajit Dash, Jordan S. Mar, Mary Keir, Laurent Peyrin-Biroulet, Julian Panes, Jean-Frederic Colombel, Brian Feagan, John F. Valentine, Stefan Schreiber
Efmarodocokin alfa is an interleukin (IL)-22 agonist, with favorable pharmacokinetic properties and an acceptable safety profile. This study further explored the therapeutic potential of efmarodocokin alfa compared with vedolizumab in patients with ulcerative colitis (UC).
-
The Optimal Duration of pH Monitoring: Testing the Validity of Lyon 2.0 Recommendations for Wireless pH Measurement Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Radu I. Rusu, Mark R. Fox, Rami Sweis, Sebastian Zeki, Jason M. Dunn, Angela Anggiansah, Jafar Jafari, Annastazia Learoyd, Terry Wong
The Lyon 2.0 consensus recommends 96-hour wireless pH studies for gastroesophageal reflux disease (GERD) diagnosis; however, the optimal length of pH measurement has not been established. Further, it is uncertain if, and under what circumstances, shorter recording times are sufficient for a conclusive diagnosis.
-
Hypercoagulation after Hospital Discharge in Acute Severe Ulcerative Colitis: A Prospective Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Benjamin J. Griffiths, Michael J.R. Desborough, Marjolijn Duijvestein, Geert R.A. D’Haens, Yuhong Yuan, Robert V. Bryant, Nicola Curry, Simon P.L. Travis, Vipul Jairath
Venous thromboembolism is a serious complication during and following hospitalization with acute severe ulcerative colitis (ASUC). We evaluated serial thrombotic profiles of patients with ASUC from the point of hospitalization up to 12 weeks postdischarge and compared these with control patients with quiescent ulcerative colitis.
-
Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Luc Biedermann, Christoph Schlag, Alex Straumann, Alfredo J. Lucendo, Stephan Miehlke, Michael Vieth, Cecilio Santander, Constanza Ciriza de los Rios, Christoph Schmöcker, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Albert Jan Bredenoord, Stefan Schubert, Mike Halstead, Sabrina Pfurr, Ralph Mueller, Alain M. Schoepfer, Stephen Attwood, International EOS-2 Study Group
Budesonide orodispersible tablets (BOT) have been shown to be safe and effective in phase III double-blind trials of induction and 48-week maintenance therapy of eosinophilic esophagitis (EoE). We now analyzed the long-term efficacy and safety of BOT in a 96-week open-label extension (OLE) study.
-
Global Distribution of Colorectal Cancer Staging at Diagnosis: An Evidence Synthesis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Lanwei Guo, Le Wang, Lin Cai, Yuelun Zhang, Xiaoshuang Feng, Chenxin Zhu, Wendong Gao, Rafael Cardoso, Haiyan Yang, Min Dai, Hermann Brenner, Hongda Chen
Stage at diagnosis is a key prognostic factor for colorectal cancer (CRC) survival. We aimed to assess the global distribution of CRC staging at diagnosis using population-based or hospital-based registry data.
-
Serum Albumin and Its Trajectory Are Associated With Therapeutic Outcomes in Ulcerative Colitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Jieqi Zheng, Xi Zhang, Liqian Zhang, Li Li, Minhu Chen, Rirong Chen, Shenghong Zhang
The relationship between serum albumin levels and therapeutic outcomes in ulcerative colitis (UC) has been debated. Additionally, the dynamic changes in albumin levels remain understudied.
-
Persistent Lugol-unstained Lesions: A New Predictor of Progression to Esophageal Squamous Cell Carcinoma? Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-16 Ali Soroush, Sanford M. Dawsey
-
An Elusive Pancreatic Mass Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 Kosaku Morimoto, Kazuyuki Matsumoto, Ryuta Takenaka
-
-
Reply Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 William King, Dennis Yang, Peter Draganov
-
Hepatic Artery Pseudoaneurysm After Whipple Procedure Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 Hailin Yan, Jinlin Yang, Xue Xiao
-
Health Care and Prescription Medication Affordability for Inflammatory Bowel Disease in the United States in 2023 Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
-
IgG4-related Gastrointestinal Disease Diagnosed by Underwater Endoscopic Mucosal Resection Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 Hidetaka Hamamoto, Tomoki Matsuda, Junichi Akahira
-
A Pedigree With Complement Hyperactivation, Angiopathic Thrombosis, and Severe Protein-losing Enteropathy (CHAPLE) Disease: Variable Penetrance and Treatment With Pozelimab Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 Esther Catharina Wilhelmina De Boer, Nikki Van Der Kruk, Richard Benjamin Pouw, Johan Emiel Van Limbergen, Taco W. Kuijpers
-
Assessing the Quality of Artificial Intelligence Responses and Resistance to Sycophancy in Providing Patient-centered Medical Advice on Gastroesophageal Reflux Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 Benjamin Douglas Liu, Steve D’Souza, Melina Roy, Metrohealth Dietitians, Sherif Saleh, Ronnie Fass, Gengqing Song
-
Validation and Epidemiologic Definition of the Novel Steatotic Liver Disease Nomenclature in a National United States Cohort With Cirrhosis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 Catherine Mezzacappa, Pedro Ochoa-Allemant, Marina Serper, Tamar H. Taddei, Binu V. John, David E. Kaplan, Nadim Mahmud
Novel steatotic liver disease (SLD) definitions were introduced in 2023. Accurate and meaningful classifications using clinical data are needed to study interventions and outcomes.
-
An Unusual Case of Multiple Gastric Masses: Granulocytic Sarcoma Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 Ming Zhou, Fu Guan
-
Reply to “Kidney Failure, Inflammatory Bowel Disease, and Colectomy” Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 Yuanhang Yang, Juan J. Carrero
-
A Call to Action: Unraveling the Nuance of Adapted Eating Behaviors in Individuals With Gastrointestinal Conditions Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 Kate Scarlata, Hana F. Zickgraf, Rose-Marie Satherley, Jordan M. Shapiro, Dawn W. Adams, Janelle Smith, Stacey Collins, Tiffany Taft
The primary aim of this expert narrative review is to unravel the complexities of feeding and eating disorders in the gastroenterology practice setting. We aim to critically assess current assessment screening tools for eating and feeding disorders to gain a comprehensive understanding of how these tools may be misconstrued in the context of gastrointestinal conditions. Additionally, our objective
-
Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-15 Sailish Honap, Vipul Jairath, Bruce E. Sands, Parambir S. Dulai, Peter D.R. Higgins, Peter De Cruz, Ana Gutiérrez, Paulo G. Kotze, Byong Duk Ye, Taku Kobayashi, Richard B. Gearry, Pablo A. Olivera, Aurélien Amiot, Mahmoud H. Mosli, Sameer Al Awadhi, Jonas Halfvarson, Kamal V. Patel, Shaji Sebastian, Silvio Danese, Laurent Peyrin-Biroulet
Interventional clinical trials in acute severe ulcerative colitis (ASUC) are characterized by substantial heterogeneity due to a lack of consensus in several key areas of trial design—this impedes clinical research efforts to identify novel therapies. The objective of this initiative was to achieve the first consensus and provide clear position statements on ASUC trial design.
-
Heterozygous Variant of CYP2C8∗3 is a Protective Factor for Developing Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-14 Mike J.P. De Jong, Romy N. Kuipers, Joost P.H. Drenth, René H.M. Te Morsche, Foke Van Delft, Peter D. Siersema, Dutch Pancreatitis Study Group, Christina J. Sperna Weiland, Robert C. Verdonk, Niels G. Venneman, Muhammed Hadithi, Tanya M. Bisseling, Marco J. Bruno, Erwin-Jan M. van Geenen
-
Nonalcohol-related Cirrhosis Leads to Higher 6-week Mortality After Acute Variceal Bleeding Than Alcohol-related Cirrhosis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-14 Yu Jun Wong, Adam Buckholz, Alyssa Sim, Margaret Teng, Rochelle Wong, Michael P. Curry, Marianne Anastasia De Roza, Gyorgy Baffy, Xuhui Teoh, Eric Chak, Tarun Rustagi, Jason Chang, Guan Wee Wong, Puneeta Tandon, Guadalupe Garcia-Tsao, Juan G. Abraldes, Arpan Mohanty, Brett Fortune
Acute variceal bleeding (AVB) portends significant 6-week mortality in patients with cirrhosis. It remains unclear if the correlation between liver prognostic scores and 6-week mortality are similar across different etiologies of liver cirrhosis, particularly alcohol-related liver disease (ALD) vs non-alcohol-related liver disease (non-ALD). This study aims to compare the 6-week mortality following
-
Prevalence and Prognosis of Mild Inflammatory Bowel Disease: A Population-based Cohort Study, 1997–2020 Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-13 Henrik Albaek Jacobsen, Anastasia Karachalia-Sandri, Anthony C. Ebert, Kristine H. Allin, Ashwin N. Ananthakrishnan, Manasi Agrawal, Ryan C. Ungaro, Jean-Frederic Colombel, Lone Larsen, Tine Jess
The inflammatory bowel diseases (IBDs), ulcerative colitis (UC) and Crohn’s disease (CD), are heterogenous diseases ranging from mild to severe. We aimed to describe the prevalence and prognosis of mild IBD in an unselected population-based patient cohort.
-
Comparative Efficacy and Safety of Endoscopic Modalities for Colorectal Cancer Screening in Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-13 Vasiliki Sinopoulou, Gaurav B. Nigam, Morris Gordon, Meghana Ganeshan, Mitchell Rudo Tokonyai, Sunil Dolwani, Marietta Iacucci, Matt Rutter, Venkat Subramanian, Ana Wilson, James E. East, British Society of Gastroenterology Colorectal IBD Surveillance Guideline Development Group, Ibrahim Al Bakir, Adrian Bateman, Shahida Din, Anjan Dhar, Omar Faiz, Bu Hayee, Chris Healey, Chris A. Lamb, Simon Leedham
Long-standing inflammatory bowel disease (IBD) increases the risk of colonic neoplasia, necessitating effective screening strategies. This network meta-analysis compared the efficacy and safety between different endoscopic modalities in the high-definition (HD) era.
-
Neighborhood Social Determinants of Health are Associated With Metabolic Dysfunction-associated steatotic Liver Disease Outcomes Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-13 Claire S. Faulkner, Majd B. Aboona, Likith Surendra, Pooja Rangan, Cheng Han Ng, Daniel Q. Huang, Mark Muthiah, Donghee Kim, Michael B. Fallon, Mazen Noureddin, Vincent L. Chen, Ani Kardashian, Karn Wijarnpreecha
Significant health disparities exist in metabolic dysfunction-associated steatotic liver disease (MASLD), driven by social determinants of health (SDOH). Few studies have explored neighborhood-level SDOH in MASLD.
-
Clinical, Histologic, and Safety Outcomes With Long-term Maintenance Therapies for Eosinophilic Esophagitis: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-13 Alberto Barchi, Luca Massimino, Francesco Vito Mandarino, Mona-Rita Yacoub, Luca Albarello, Edoardo Vincenzo Savarino, Federica Ungaro, Silvio Danese, Sandro Passaretti, Albert J. Bredenoord, Edoardo Vespa
Our aim was to evaluate the outcomes of maintenance treatments for eosinophilic esophagitis (EoE) among observational studies (OSs) and randomized controlled trials (RCTs).
-
Acute Kidney Injury in Patients with Cirrhosis and Chronic Kidney Disease: Results from the HRS-HARMONY Consortium Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-13 Shelsea A. St. Hillien, Jevon E. Robinson, Tianqi Ouyang, Kavish R. Patidar, Justin M. Belcher, Giuseppe Cullaro, Kevin R. Regner, Raymond T. Chung, Nneka Ufere, Juan Carlos Q. Velez, Javier A. Neyra, Sumeet K. Asrani, Hani Wadei, J. Pedro Teixeira, Danielle L. Saly, Josh Levitsky, Eric Orman, Deirdre Sawinski, Leigh Anne Dageforde, Andrew S. Allegretti, HRS-HARMONY Consortium
Chronic kidney disease (CKD) frequency is increasing in patients with cirrhosis and these individuals often experience acute kidney injury (AKI). Direct comparisons of outcomes between AKI-only versus AKI on CKD (AoCKD) among patients with cirrhosis are not well described.
-
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-13 Vincenza Calvaruso, Ciro Celsa, Laura Cristoferi, Miki Scaravaglio, Rachel Smith, Senamjit Kaur, Gabriele Di Maria, Luigi Capodicasa, Grazia Pennisi, Alessio Gerussi, Eugenia Nofit, Federica Malinverno, Pietro Lampertico, Nora Cazzagon, Marco Marzioni, Umberto Vespasiani-Gentilucci, Francesca Colapietro, Pietro Andreone, Ana Lleo De Nalda, Cristina Rigamonti, Mauro Viganò, Edoardo Giovanni Giannini
Noninvasive tests (NITs) for ruling-out clinical significant portal hypertension (CSPH) and high-risk varices (HRVs) in patients with primary biliary cholangitis (PBC) and compensated advanced chronic liver disease (cACLD) are lacking. We evaluated NITs in these patients and the influence of cholestasis on their performance.
-
Global Epidemiology and Characteristics of Metabolic-associated Steatotic Liver Disease in Type 1 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-11 Matheus Souza, Lubna Al-Sharif, Samira M. Khalil, Cristiane Alves Villela-Nogueira, Alessandro Mantovani
Metabolic dysfunction-associated steatotic liver disease (MASLD) is often overlooked in patients with type 1 diabetes mellitus (T1DM). Our study aims to provide a comprehensive overview of the burden of MASLD in T1DM by assessing the prevalence of MASLD and its advanced forms in individuals with T1DM.
-
Lipoprotein (a) in the Full Spectrum of Metabolic Dysfunction-associated Steatotic Liver Disease: Evidence From Histologically and Genetically Characterized Cohorts Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-11 Hong Fan, Matina Kouvari, Geltrude Mingrone, Jacob George, Georgios Papatheodoridis, Laura Valenzuela-Vallejo, Zhenqiu Liu, Xingdong Chen, Tiejun Zhang, Christos S. Mantzoros
Lipoprotein(a) (Lp(a)) is an emerging biomarker for cardiometabolic factors. We studied the role of Lp(a) in the full spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD).
-
One Year of Gluten-Free Diet Impacts Gut Function and Microbiome in Celiac Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-09 Carolyn M. Costigan, Frederick J. Warren, Anthony P. Duncan, Caroline L. Hoad, Nina Lewis, Trevor Hill, Colin J. Crooks, Paul S. Morgan, Carolina Ciacci, Paola Iovino, David S. Sanders, Falk Hildebrand, Penny A. Gowland, Robin C. Spiller, Luca Marciani
Currently, the main treatment for celiac disease (CD) is the gluten-free diet (GFD). This observational cohort study investigated the impact of CD and 1 year of GFD on gut function and microbiome.
-
-
Outcomes After Dose Intensification of Risankizumab for Crohn’s Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-09 Rahul S. Dalal, Heidy J. Cabral, Alex Carlin, Matthew P. Ilse, Jessica R. Allegretti
-
The Impact and Interactions of Race and Gender on Healthcare Use and Spending Irritable Bowel Syndrome Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-09 Andrea Shin, Rachel Sarnoff, Arpana Church, Huiping Xu, Lin Chang MD
Studies examining the effects of social determinants of health on healthcare use in irritable bowel syndrome (IBS) are scarce. We aimed to assess healthcare spending among different racial/ethnic groups and genders in adults with IBS.
-
-
A Roadmap to a Successful Job Search for Gastroenterology Trainees Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-12-04 Netanel Zilberstein, Indira Bhavsar-Burke
-
Older Age But Not Comorbidity is Associated with Worse Survival in Patients with Hepatocellular Carcinoma Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-11-20 Mounika Kanneganti, Mohammed Al-Hasan, Samantha Bourque, Sneha Deodhar, Ju Dong Yang, Daniel Q. Huang, Anand V. Kulkarni, Purva Gopal, Neehar D. Parikh, Fasiha Kanwal, Madhukar S. Patel, Amit G. Singal
Age and comorbidity are key factors in assessing patient prognosis and informing stopping rules for cancer screening eligibility, but their impact has not been rigorously evaluated in patients with hepatocellular carcinoma (HCC).
-
Prognostic Communication, Symptom Burden, Psychological Distress, and Quality of Life Among Patients With Decompensated Cirrhosis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-11-19 John Donlan, Alyson Kaplan, Alan Noll, Kedie Pintro, Nora Horick, Chengbo Zeng, Maria Edelen, Zainab Soetan, Cameron Comrie, Teresa Indriolo, Lucinda Li, Enya Zhu, Malia E. Armstrong, Leah L. Thompson, Joyce Zhou, Michelle S. Diop, Nancy Mason, Kirsten G. Engel, Michaela Rowland, Sara Kenimer, Karen O’Brien, Jennifer C. Lai, Vicki Jackson, Raymond T. Chung, Areej El-Jawahri, Nneka N. Ufere
Timely prognostic communication is a critical component of care for patients with decompensated cirrhosis (DC). However, few studies have examined the association of prognostic communication with symptoms, mood, and health-related quality of life (HRQOL) in this population.
-
A Predictive Model Based on Quantitative Fecal Immunochemical Test Can Stratify the Risk of Colorectal Cancer in an Organized Screening Program Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-11-19 Leonardo Frazzoni, Silvia Pecere, Cesare Hassan, Lorenzo Fuccio, Livio Enrico Del Vecchio, Carlo Fabbri, Arrigo Arrigoni, Paola Cassoni, Dario Mazzucco, Lorenzo Orione, Giulia Gibiino, Alessandro Repici, Cristiano Spada, Federico Iacopini, Carlo Senore, Giulio Antonelli
A significant number of post fecal immunochemical test (FIT) colonoscopies in European-organized colorectal cancer (CRC) screening programs are performed beyond the recommended 31-day threshold due to overburdened colonoscopy services. We aimed to develop a simple predictive model to stratify CRC risk of FIT+ patients.
-
Daily or Twice Daily Treatment with Topical Steroids Results in Similar Responses in Eosinophilic Esophagitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-11-17 Craig C. Reed, Sean S. LaFata, Timothy S. Gee, Hannah L. Thel, Brenderia A. Cameron, Angela Z. Xue, Akshatha Kiran, Adolfo A. Ocampo, Justin McCallen, Christopher J. Lee, Stephanie A. Borinsky, Walker D. Redd, Trevor Barlowe, Rayan N. Kaakati, Cary C. Cotton, Swathi Eluri, Evan S. Dellon
Few data compare topical corticosteroid (tCS) dosing regimens and outcomes. We aimed to compare treatment outcomes in patients with eosinophilic esophagitis (EoE) by once or twice daily dosing regimens.
-
Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-11-16 David Marti-Aguado, José Miguel Carot-Sierra, Aida Villalba-Ortiz, Harris Siddiqi, Rose Marie Vallejo-Vigo, Carmen Lara-Romero, Marta Martín-Fernández, Matías Fernández-Patón, Clara Alfaro-Cervello, Ana Crespo, Elena Coello, Víctor Merino-Murgui, Egbert Madamba, Salvador Benlloch, Judith Pérez-Rojas, Víctor Puglia, Antonio Ferrández, Victoria Aguilera, Cristina Monton, Desamparados Escudero-García
A noteworthy proportion of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) have an indeterminate vibration-controlled transient elastography (VCTE). Among these patients, we aimed to identify candidates for MASLD treatment by diagnosing significant fibrosis.